BioNexus Gene Lab Corp.
BioNexus Gene Lab Corp. (BGLC) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
bglc · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Medical - Diagnostics & Research · 5 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
BioNexus Gene Lab Corp.You BGLC | $4M | N/A | — | -$1.20 |
 Advanced Biomed Inc. Common Stock ADVB | $4M | N/A | — | -$0.09 |
 AEON Biopharma, Inc. AEON | $9M | N/A | — | -$3.95 |
 Aptorum Group Limited APM | $7M | N/A | — | -$0.19 |
 Check-Cap Ltd. CHEK | $11M | N/A | — | -$4.30 |
 Lifeward Ltd. LFWD | $11M | N/A | — | -$1.72 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for BioNexus Gene Lab Corp. (BGLC) measures how much investors pay for each dollar of the company's trailing earnings. BGLC's current PE ratio of N/A is calculated by dividing its stock price of $2.19 by its TTM earnings per share of -$1.20.
Frequently asked questions
BGLC pe ratio · 6 questionsBGLC's current PE ratio is N/A as of 2026-06-09, based on a stock price of $2.19 and TTM EPS of -$1.20. Data sourced from Financial Modeling Prep via BGLC's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · BioNexus Gene Lab Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09